hotspot -WSS

hotspot

author：knowledge 2025-09-30 23:06:50 - browse：76

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

WSS

Ukraine seeks to reclaim its role as a hub for clinical trials

As AI regulations shape up, health tech startups beg for clarity

Health insurers say they are turning to AI to cut costs, improve care

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Surprise medical billing ban raises prices elsewhere

Heat waves linked to early deliveries, preterm births in new study

explore

hotspot

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Latest bird flu infection made farmworker sicker than earlier cases

Tori Bowie and the unacceptable rates of Black maternal death

Addiction doctors spar with methadone clinics over legislation

Virginia high school admissions case could be legal follow

Secretariat’s lessons for human medicine

In Memoriam: Notable people who died in 2023

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

BioMarin wins approval for gene therapy to treat hemophilia A

Flagship Pioneering startup Sonata Therapeutics lays off 21

explore

Do more moles mean more problems? Not so, says new study

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

David Sabatini, ex

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Dark money group runs ads on China biotech bill

explore

focus

entertainment

focus